Drugs / Sacubitril/Valsartan
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2/3 | NCT05366101 Comparator | Apr 2019 → Feb 2022 | hypertrophic cardiomyopathy | Newcastle-upon-Tyne Hospitals NHS Trust | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sacubitril/Valsartan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05366101 ↗ |
| Route | Oral | “each taken by mouth twice daily” NCT05366101 ↗ |